Metabolic profiling and antibacterial activity of Eryngium pristis Cham. & Schltdl. - prospecting for its use in the treatment of bacterial infections
Archives of Pharmacy and Pharmaceutical Sciences · 2021
DOI: 10.29328/journal.apps.1001027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Pharmacy and Pharmaceutical Sciences, 2021. Verfasst von Daniela Laura Silva Fernandes und 9 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Morbidity and mortality of the infected patients by multidrug-resistant bacteria have increased, emphasizing the urgency of fight for the discovery of new innovative antibiotics. In this sense, natural products emerge as valuable sources of bioactive compounds. Among the biodiversity, Eryngium pristis Cham. & Schltdl. (Apiaceae Lindl.) is traditionally used to treat thrush and ulcers of throat and mouth, as diuretic and emmenagogue, but scarcely known as an antimicrobial agent. With this context in mind, the goals of this study were to investigate the metabolic profile and the antibacterial activity of ethanolic extract (EE-Ep) and hexane (HF-Ep), dichloromethane (DF-Ep), ethyl acetate (EAF-Ep) and butanol (BF-Ep) fractions from E. pristis leaves. Gas Chromatography-Mass Spectrometry (GC-MS) was performed to stablish the metabolic profile and revealed the presence of 12 and 14 compounds in EAF-Ep and HF-Ep, respectively. β-selinene, spathulenol, globulol, 2-methoxy-4-vinylphenol, α-amyrin, β-amyrin, and lupeol derivative were some of phytochemicals identified. The antibacterial activity was determined by Minimal Inhibitory Concentration (MIC) using the broth micro-dilution against eight ATCC® and five methicillin-resistant Staphylococcus aureus (MRSA) clinical strains. HF-Ep was the most effective (MIC ≤ 5,000 µg/µL), being active against the largest part of tested Gram-positive and Gram-negative bacterial strains, including MRSA, with exception of Escherichia coli (ATCC 25922) and Pseudomonas aeruginosa (ATCC 9027) and (ATCC 27853). These results suggest that E. pristis is a natural source of bioactive compounds for the search of new antibiotics which can be an interesting therapeutic approach to recover patients mainly infected by MRSA strains.
Zitieren
APA
Fernandes, D. L. S., Costa, Y. F. G. D., Bessa, M. E. D., Ferreira, A. L. P., Corrêa, J. O. D. A., Vieira, G. D., Sousa, O. V. D., Araújo, A. L. S. D. M., Castilho, P. C., & Alves, M. S. (2021). Metabolic profiling and antibacterial activity of Eryngium pristis Cham. & Schltdl. - prospecting for its use in the treatment of bacterial infections. Archives of Pharmacy and Pharmaceutical Sciences. https://doi.org/10.29328/journal.apps.1001027
Vancouver
Fernandes DLS, Costa YFGD, Bessa MED, Ferreira ALP, Corrêa JODA, Vieira GD, et al. Metabolic profiling and antibacterial activity of Eryngium pristis Cham. & Schltdl. - prospecting for its use in the treatment of bacterial infections. Archives of Pharmacy and Pharmaceutical Sciences. 2021. doi:10.29328/journal.apps.1001027
BibTeX
@article{Fernandes2021,
author = {Fernandes, Daniela Laura Silva and Costa, Ygor Ferreira Garcia Da and Bessa, Martha Eunice De and Ferreira, Adriana Lucia Pires and Corrêa, José Otávio do Amaral and Vieira, Glauciemar Del-Vechio and Sousa, Orlando Vieira De and Araújo, Ana Lúcia Santos De Matos and Castilho, Paula C and Alves, Maria Silvana},
title = {Metabolic profiling and antibacterial activity of Eryngium pristis Cham. & Schltdl. - prospecting for its use in the treatment of bacterial infections},
journal = {Archives of Pharmacy and Pharmaceutical Sciences},
year = {2021},
doi = {10.29328/journal.apps.1001027}
}
EUVIMED